{"title": "How prostate cancer becomes treatment resistant", "title_detail": {"type": "text/plain", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/pharmaceuticals.xml", "value": "How prostate cancer becomes treatment resistant"}, "links": [{"rel": "alternate", "type": "text/html", "href": "https://www.sciencedaily.com/releases/2019/02/190228141417.htm"}], "link": "https://www.sciencedaily.com/releases/2019/02/190228141417.htm", "summary": "Scientists have identified how prostate cancer transforms into a deadly treatment-resistant prostate cancer subtype called neuroendocrine prostate cancer (NEPC) following treatment with anti-androgen therapy. Their findings -- which include the metabolic rewiring and the epigenetic alteration that drives this switch -- reveal that an FDA-approved drug holds potential as a NEPC treatment.", "summary_detail": {"type": "text/html", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/pharmaceuticals.xml", "value": "Scientists have identified how prostate cancer transforms into a deadly treatment-resistant prostate cancer subtype called neuroendocrine prostate cancer (NEPC) following treatment with anti-androgen therapy. Their findings -- which include the metabolic rewiring and the epigenetic alteration that drives this switch -- reveal that an FDA-approved drug holds potential as a NEPC treatment."}, "published": "Thu, 28 Feb 2019 14:14:17 EST", "published_parsed": [2019, 2, 28, 19, 14, 17, 3, 59, 0], "id": "https://www.sciencedaily.com/releases/2019/02/190228141417.htm", "guidislink": false}